Innate Pharma announces its revenue for the first quarter of 2012 and updates on its cash position

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces revenue of 3.0 million euros for the first quarter of 2012, compared with 1.0 million euros for the same period in 2011. During the first quarter of 2012, this revenue resulted from Innate Pharma’s collaboration and licensing agreement with Bristol-Myers Squibb, signed in July 2011.

Cash, cash equivalents and current financial instruments of the Company amounted to 41.6 million euros at March 31, 2012 compared with 30.4 million euros at March 31, 2011.